GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LadRx Corp (STU:CX5) » Definitions » Net Margin %

LadRx (STU:CX5) Net Margin % : 0.00% (As of Dec. 2023)


View and export this data going back to 1986. Start your Free Trial

What is LadRx Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. LadRx's Net Income for the three months ended in Dec. 2023 was €-0.79 Mil. LadRx's Revenue for the three months ended in Dec. 2023 was €0.00 Mil. Therefore, LadRx's net margin for the quarter that ended in Dec. 2023 was 0.00%.

The historical rank and industry rank for LadRx's Net Margin % or its related term are showing as below:


STU:CX5's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -155.67
* Ranked among companies with meaningful Net Margin % only.

LadRx Net Margin % Historical Data

The historical data trend for LadRx's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LadRx Net Margin % Chart

LadRx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

LadRx Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of LadRx's Net Margin %

For the Biotechnology subindustry, LadRx's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LadRx's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LadRx's Net Margin % distribution charts can be found below:

* The bar in red indicates where LadRx's Net Margin % falls into.



LadRx Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

LadRx's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=0.367/0
= %

LadRx's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin=Net Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-0.787/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


LadRx  (STU:CX5) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


LadRx Net Margin % Related Terms

Thank you for viewing the detailed overview of LadRx's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


LadRx (STU:CX5) Business Description

Traded in Other Exchanges
Address
11726 San Vicente Boulevard, Suite 650, Los Angeles, CA, USA, 90049
LadRx Corp operates as a biopharmaceutical research and development company in the healthcare sector of the United States. It is focused on the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company develops Aldoxorubicin, which is meant to cure soft tissue sarcoma, a kind of tumor. It also develops Arimoclomol which is in development in Niemann Pick disease Type C (NPC) and Gaucher disease.

LadRx (STU:CX5) Headlines

No Headlines